Merck Pre-Tax Profit Margin 2010-2023 | MRK
Current and historical pre-tax profit margin for Merck (MRK) from 2010 to 2023. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Merck pre-tax profit margin for the three months ending December 31, 2023 was .
| Merck Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2023-12-31 |
$60.12B |
$1.89B |
3.14% |
| 2023-09-30 |
$59.31B |
$7.45B |
12.56% |
| 2023-06-30 |
$58.31B |
$5.41B |
9.28% |
| 2023-03-31 |
$57.87B |
$15.23B |
26.32% |
| 2022-12-31 |
$59.28B |
$16.44B |
27.74% |
| 2022-09-30 |
$58.97B |
$16.84B |
28.55% |
| 2022-06-30 |
$57.17B |
$18.52B |
32.40% |
| 2022-03-31 |
$53.98B |
$15.75B |
29.18% |
| 2021-12-31 |
$48.70B |
$13.88B |
28.50% |
| 2021-09-30 |
$44.36B |
$6.55B |
14.76% |
| 2021-06-30 |
$42.14B |
$3.99B |
9.46% |
| 2021-03-31 |
$40.09B |
$5.01B |
12.50% |
| 2020-12-31 |
$41.52B |
$5.86B |
14.12% |
| 2020-09-30 |
$36.49B |
$7.78B |
21.33% |
| 2020-06-30 |
$37.96B |
$7.42B |
19.56% |
| 2020-03-31 |
$40.36B |
$7.94B |
19.68% |
| 2019-12-31 |
$39.12B |
$7.17B |
18.33% |
| 2019-09-30 |
$45.97B |
$11.28B |
24.53% |
| 2019-06-30 |
$44.37B |
$11.60B |
26.14% |
| 2019-03-31 |
$43.07B |
$10.42B |
24.20% |
| 2018-12-31 |
$42.29B |
$8.70B |
20.57% |
| 2018-09-30 |
$41.73B |
$7.98B |
19.11% |
| 2018-06-30 |
$41.26B |
$5.51B |
13.35% |
| 2018-03-31 |
$40.73B |
$5.86B |
14.40% |
| 2017-12-31 |
$40.12B |
$6.52B |
16.25% |
| 2017-09-30 |
$39.80B |
$3.29B |
8.26% |
| 2017-06-30 |
$40.02B |
$5.97B |
14.93% |
| 2017-03-31 |
$39.93B |
$5.04B |
12.62% |
| 2016-12-31 |
$39.81B |
$4.66B |
11.70% |
| 2016-09-30 |
$39.91B |
$6.83B |
17.12% |
| 2016-06-30 |
$39.44B |
$6.34B |
16.08% |
| 2016-03-31 |
$39.39B |
$5.64B |
14.33% |
| 2015-12-31 |
$39.50B |
$5.40B |
13.67% |
| 2015-09-30 |
$39.77B |
$16.40B |
41.23% |
| 2015-06-30 |
$40.25B |
$15.49B |
38.48% |
| 2015-03-31 |
$41.40B |
$16.57B |
40.03% |
| 2014-12-31 |
$42.24B |
$17.28B |
40.92% |
| 2014-09-30 |
$43.08B |
$6.70B |
15.55% |
| 2014-06-30 |
$43.55B |
$6.73B |
15.46% |
| 2014-03-31 |
$43.63B |
$6.09B |
13.95% |
| 2013-12-31 |
$44.03B |
$5.55B |
12.59% |
| 2013-09-30 |
$44.45B |
$5.65B |
12.72% |
| 2013-06-30 |
$44.91B |
$6.35B |
14.13% |
| 2013-03-31 |
$46.21B |
$7.78B |
16.84% |
| 2012-12-31 |
$47.27B |
$8.74B |
18.49% |
| 2012-09-30 |
$47.82B |
$8.99B |
18.79% |
| 2012-06-30 |
$48.36B |
$9.12B |
18.86% |
| 2012-03-31 |
$48.20B |
$8.11B |
16.83% |
| 2011-12-31 |
$48.05B |
$7.33B |
15.26% |
| 2011-09-30 |
$47.85B |
$5.05B |
10.56% |
| 2011-06-30 |
$46.95B |
$3.20B |
6.81% |
| 2011-03-31 |
$46.15B |
$2.77B |
5.99% |
| 2010-12-31 |
$45.99B |
$1.65B |
3.59% |
| 2010-09-30 |
$43.99B |
$8.82B |
20.05% |
| 2010-06-30 |
$38.91B |
$13.40B |
34.43% |
| 2010-03-31 |
$33.47B |
$14.12B |
42.20% |
| 2009-12-31 |
$27.43B |
$15.29B |
55.75% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$317.566B |
$60.115B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
